Abiopharma

🔍 Burrows Scott L (Executive)

Company: Spyre Therapeutics, Inc. (SYRE)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 140,000 shares of Stock Option (Right to Buy) at $30.61 per share (Derivative)
  Date: 2026-01-09 | Code: A | Expires: 2036-01-09 | equity_swap_involved: 0 | shares_owned_after: 140,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.